Abstract: A process for the purification of proteins from solutions containing contaminants of similar net charge and molecular weight is provided, comprising contacting a solution containing the desired protein with an immobilized metal affinity chromatography resin in a buffer containing a low concentration of a weak ligand for the chelant of the resin. The adsorbed protein is then eluted using a buffer having a high concentration of the same weak ligand, e.g., Tris. Particularly preferred features employ agarose-iminodiacetic acid resins having copper cations and are especially useful in obtaining preparations of homogeneous, stable rsT4 proteins.

Abstract: DNA sequences, hybrid DNA sequences, recombinant DNA molecules and processes for producing streptavidin-like polypeptides and for producing fused proteins consisting of a streptavidin-like polypeptide joined end to end with another protein, polypeptide, peptide or amino acid. The DNA sequences, hybrid DNA sequences and recombinant DNA molecules of this invention are characterized in that they include DNA fragments that code for streptavidin-like polypeptides. These DNA sequences, hybrid DNA sequences and recombinant DNA molecules and the hosts transformed with them may be employed in the processes of this invention to produce streptavidin-like polypeptides and fused proteins.

Abstract: This invention relates to the immunotherapeutic treatment of allergies. More particularly, this invention relates to a process for treating allergies by administering to a mammal a pharmaceutically effective amount of gamma interferon.

Abstract: A polynucleotide probe with a label bearing a plurality of signalling moieties. The label is attached to the probe by the reaction of an amino and sulfhydryl reactive hetero bifunctional reagent with the probe and label, the reaction resulting in the oxidation of a sulfhydryl group of the label. The label may be attached to the 5' terminus of the probe, or to modified bases of the probe. Probes constructed according to the invention are useful in detecting target sequences in genomic DNA.

Abstract: Improved secretion of heterologous proteins by hosts such as yeast by using promoters of at most intermediate strength with heterologous DNA secretion signal sequences is disclosed. A promoter of at most intermediate strength, such as the actin (ACT) or iso-1-cytochrome c (CYC1) promoter in S. cerevisiae is operatively linked to a DNA signal sequence, such as the Mf.alpha.1 signal sequence. A DNA sequence for a selected protein, such as somatomedin C (SMC), tissue plasminogen activator (TPA) or tumor necrosis factor (TNF), may be operatively linked to the DNA signal sequence.

Abstract: DNA sequences, recombinant DNA molecules and hosts transformed with them which produce human lipocortin-like polypeptides and methods of making and using these products. The DNA sequences and recombinant DNA molecules are characterized in that they code on expression for a human lipocortin-like polypeptide. In appropriate hosts these DNA sequences permit the production of human lipocortin-like polypeptides useful as anti-inflammatory agents and methods in the treatment of arthritic, allergic, dermatologic, ophthalmic and collagen diseases as well as other disorders involving inflammatory processes.

Abstract: DNA sequences coding for at least one MIS-like polypeptide, recombinant DNA molecules comprising such sequences, hosts comprising such sequences and processes for producing such polypeptides in hosts transformed with those DNA sequences. The MIS-like polypeptides are useful in the treatment of ovarian cancer and other susceptible cancers.

Abstract: This invention relates to peptides involved in the pathogenesis of human immunodeficiency virus ("HIV"). More particularly, this invention relates to peptides from the env region of the HIV genome and the use of such peptides in methods and compositions for preventing, treating, or detecting acquired immune deficiency syndrome ("AIDS") infection.

Abstract: This invention relates to combinations and methods for the treatment of malignant and non-malignant diseases. More particularly, this invention relates to combinations of natural or recombinant tumor necrosis factors ("TNF") and non-steroidal anti-inflammatory agents, such as indomethacin and ibuprofen, useful for the growth inhibition or killing of transformed cells. According to this invention, the non-steroidal anti-inflammatory agents are used to reduce or eliminate the toxic side effects of high doses of TNFs employed in the treatment of malignant and non-malignant neoplastic diseases. Advantageously, the combinations and methods of this invention allow the administration of higher doses of TNF than those tolerated in conventional treatment regimens based upon TNF alone.

Abstract: An improved method, employing electroporation, for producing novel recombinant host cells characterized by stably integrated foreign DNA at high copy number. These recombinant host cells are useful in the efficient, large-scale production of recombinant proteins and polypeptides.

Abstract: Polypeptides that bind to CD2, the receptor on the surface of T-lymphocytes. Most preferably, the polypeptides bind to CD2 on the surface of T-lymphocytes and inhibit adhesion between T-lymphocytes and target cells. DNA sequences that code on expression in appropriate unicellular hosts for those polypeptides. Methods of making and using those polypeptides in therapy and diagnosis.

Abstract: DNA sequences, recombinant DNA molecules and hosts transformed with them which produce human lipocortin-like polypeptides and methods of making and using these products. The DNA sequences and recombinant DNA molecules are characterized in that they code on expression for a human lipocortin-like polypeptide. In appropriate hosts these DNA sequences permit the production of human lipocortin-like polypeptides useful as anti-inflammatory agents and methods in the treatment of arthritic, allergic, dermatologic, ophthalmic and collagen diseases as well as other disorders involving inflammatory processes.

Abstract: An enzyme for conversion of 2,5-diketo-D-gluconate (2,5-DKG) to 2-keto-L-gulonic acid (2-KLG) and a genetically modified organism that expresses all the fermentation enzymes needed to convert glucose to 2-KLG (a precursor to ascorbic acid) using the new enzyme are described. Preferably, the organism is Erwinia citreus, or a mutated strain of Erwinia citreus, unable to use 2,5-DKG or 2-KLG as a sole carbon source, into which the gene for a 2,5-DKG reductase, produced by Corynebacterium sp., SHS 752001, has been inserted. The preferred transformed organism expresses the fermentation enzymes Erwinia citreus normally expresses for fermentation of glucose to 2,5-DKG and, in addition, an enzyme Corynebacterium sp. SHS 752001 expresses for fermentation of 2,5-DKG to 2-KLG.

Abstract: This invention relates to peptides involved in the pathogenesis of human immunodeficiency virus ("HIV"). More particularly, this invention relates to peptides from the env region of the HIV genome and the use of such peptides in methods and compositions for preventing, treating, or detecting acquired immune deficiency syndrome ("AIDS") infection.

Abstract: This invention relates to compositions and methods useful for the stabilization of interferons. More particularly, this invention relates to the formulation of gamma interferons with lactobionic acid in an acetate/glycine buffer.

Abstract: Surface antigens of swine mycoplasma, such antigens prepared by recombinant DNA methods, a swine mycoplasma vaccine, based on such antigens, methods of treating swine to prevent enzootic pneumonia using that vaccine, and diagnostic tests based on these antigens or antibodies raised against them for detecting the presence of swine mycoplasma infections in swine herds, and DNA sequences that code for such antigens are disclosed.

Abstract: DNA sequences, recombinant DNA molecules and hosts transformed with them which produce human phospholipase inhibitor polypeptides and methods of making and using these products. The DNA sequences and recombinant DNA molecules are characterized in that they code on expression for a human phospholipase inhibitor polypeptide. In appropiate hosts these DNA sequences permit the production of human phospholipase inhibitor polypeptides.

Abstract: Improved vectors and methods for expressing cloned genes of prokaryotic or eukaryotic origin and methods of making such vectors are disclosed, the improved vectors comprising promoters and operators from .lambda. phages and preferably do not include an active cro gene or an active N gene, the vectors having at least one endonuclease recognition site for cloning desired genes less than about 300 base pairs from the promoters and operators and being useful, as are methods utilizing the vectors, in producing a wide variety of prokaryotic, eukaryotic and viral polypeptides, hormones, enzymes, antigens, proteins and amino acids.

Abstract: DNA sequences, recombinant DNA molecules and hosts transformed with them which produce human phospholipase inhibitor-like polypeptides and methods of making and using these products. The DNA sequences and recombinant DNA molecules are characterized in that they code on expression for a human phospholipase inhibitor-like polypeptide. In appropriate hosts these DNA sequences permit the production of human phospholipase inhibitor-like polypeptides useful as anti-inflammatory agents and methods in the treatment of arthritic, allergic, dermatologic, ophthalmic and collagen diseases as well as other disorders involving inflammatory processes.

Abstract: This invention relates to the production of recombinant proteins in mammals' milk. Particularly, this invention relates to an expression system comprising the mammal's casein promoter which when transgenically incorporated into a mammal permits the female species of that mammal to produce the desired recombinant protein in or along with its milk. This invention also relates to the transgenic mammal that produces the desired recombinant product in its milk.